Mr. Francois Roberge reports
LSL PHARMA GROUP ANNOUNCES CHANGE OF AUDITORS AND GRANT OF OPTIONS
LSL Pharma Group Inc. has changed its auditor from KPMG LLP to Audacie Inc.
The predecessor auditor has resigned as auditor of the corporation, effective Sept. 25, 2024, at the request of the corporation to facilitate the appointment of Audacie as successor auditor of the corporation. The board of directors of the corporation, on the recommendation of the corporation's audit committee, approved the appointment of the successor auditor to replace the predecessor auditor, effective Sept. 25, 2024.
There were no modified opinions in the predecessor auditor's audit reports relating to the fiscal year ended Dec. 31, 2023, or any subsequent period until its resignation date, and there is no reportable event, as such term is defined in Part 4.11 of National Instrument 51-102 -- Continuous Disclosure Obligations.
The corporation has filed the change-of-auditor reporting package on SEDAR+, in accordance with NI 51-102.
Grant of stock options
The corporation has granted an aggregate of 465,270 stock options to certain officers and directors, in accordance with the corporation's long-term incentive compensation plan. The options will be exercisable at a price of 45 cents per Class A common share, vest over three years and have a 10-year term.
About LSL Pharma Group Inc.
LSL Pharma Group is an integrated, Canadian-based pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.